Patents by Inventor Kyle Atkinson

Kyle Atkinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20220411469
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: April 28, 2022
    Publication date: December 29, 2022
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei MIAO, Kyle ATKINSON, Sandra BIROC, Timothy BUSS, Melissa NEAL, Vadim KRAYNOV, Robin MARSDEN, Jason PINKSTAFF, Lillian SKIDMORE, Ying SUN, Agnieszka SZYDLIK, Delia Ianina LOPEZ DE VALENTA
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 11420999
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: August 23, 2022
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20210277056
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 9, 2021
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei MIAO, Kyle ATKINSON, Sandra BIROC, Timothy BUSS, Melissa NEAL, Vadim KRAYNOV, Robin MARSDEN, Jason PINKSTAFF, Lillian SKIDMORE, Ying SUN, Agnieszka SZYDLIK, Delia Ianina LOPEZ DE VALENTA
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 10954270
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 23, 2021
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20180009845
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 11, 2018
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei Maio, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jaosn Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Lanina Lopez De Valenta
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 9796754
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: October 24, 2017
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • Modified animal erythropoietin polypeptides and their uses
    Patent number: 9644014
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: May 9, 2017
    Assignees: Ambrx, Inc., Eli Lilly and Company
    Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
  • Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives
    Publication number: 20160052966
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: May 24, 2012
    Publication date: February 25, 2016
    Applicant: AMBRX, INC.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun
  • MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES
    Publication number: 20160024166
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.
    Type: Application
    Filed: September 15, 2015
    Publication date: January 28, 2016
    Inventors: Feng TIAN, Anna-Maria A. HAYS PUTNAM, Frank SONG, Stephanie CHU, Joseph SHEFFER, Richard S. BARNETT, Marc SILADI, Kyle ATKINSON, Darin LEE, Peter C. CANNING
  • Modified animal erythropoietin polypeptides and their uses
    Patent number: 9156899
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: October 13, 2015
    Assignees: ELI LILLY AND COMPANY, AMBRX, INC.
    Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
  • Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives
    Publication number: 20150080559
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: May 24, 2012
    Publication date: March 19, 2015
    Applicant: AMBRX, INC.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Mardsen, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Ianina Valenta
  • MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES
    Publication number: 20140011740
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 9, 2014
    Applicants: Eli Lilly Company, Ambrx, Inc.
    Inventors: Feng TIAN, Anna-Maria A. HAYS PUTNAM, Frank SONG, Stephanie CHU, Joseph SHEFFER, Richard S. BARNETT, Marc SILADI, Kyle ATKINSON, Darin LEE, Peter C. CANNING
  • Modified animal erythropoietin polypeptides and their uses
    Patent number: 8569233
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provide.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: October 29, 2013
    Assignees: Eli Lilly and Company, AMBRX, Inc.
    Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
  • MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES
    Publication number: 20130017995
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provide.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 17, 2013
    Applicants: ELI LILLY AND COMPANY, AMBRX, INC.
    Inventors: Feng TIAN, Anna-Maria A. HAYS PUTNAM, Frank SONG, Stephanie CHU, Joseph SHEFFER, Richard S. BARNETT, Marc E. SILADI, Kyle ATKINSON, Darin LEE, Peter C. CANNING
  • Modified animal erythropoietin polypeptides and their uses
    Patent number: 8278418
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provide.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 2, 2012
    Assignee: Ambrx, Inc.
    Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc E. Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
  • MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES
    Publication number: 20100093608
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provide.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 15, 2010
    Applicants: AMBRX, INC., ELI LILLY AND COMPANY
    Inventors: Feng TIAN, Anna-Maria A. HAYS PUTNAM, Frank SONG, Stephanie CHU, Joseph SHEFFER, Richard S. BARNETT, Marc E. SILADI, Kyle ATKINSON, Darin LEE, Peter C. CANNING